Berwyn, PA, United States of America

Frederick C Novello

This inventor holds 27 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignee: Merck + Co., Inc.. Active years: 1976-1987.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frederick C Novello. Retrieved from https://idiyas.com/inventor/frederick-c-novello

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 1.8

ph-index = 9

Forward Citations = 317(Granted Patents)


Company Filing History:


Years Active: 1976-1987

Loading Chart...
Areas of Expertise:
Cholesterol Synthesis
Substituted Pyranones
1,2,4-Triazoles
Bronchodilators
Anti-Hyperuricemia
Inhibitors
Trifluoromethylimidazoles
Benzothiadiazines
Pyrazinyl Compounds
Oxidase Inhibition
Arylimidazoles
Thio Products
27 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Frederick C. Novello

Introduction: Frederick C. Novello, based in Berwyn, PA, is a notable inventor with a significant portfolio of 27 patents. His groundbreaking work primarily revolves around the development of inhibitors for cholesterol synthesis, which play a crucial role in the pharmaceutical industry.

Latest Patents: Among his latest patents is a revolutionary class of substituted pyranone inhibitors of cholesterol synthesis. One notable patent details the 6-Phenyl-, phenylalkyl- and phenylethenyl-4-hydroxytetrahydropyran-2-ones in their 4(R)-trans stereoisomeric forms, which are recognized as potent inhibitors of cholesterol synthesis. This achievement is attributed to their ability to inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Another critical patent concerns the methyl, ethyl, n-propyl, 2-(acetylamino)ethyl, or 1-(2,3-dihydroxy)propyl ester of E-(3R,5S)-7-(4'-fluoro-3,3',5-trimethyl[1,1'-biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acid, which demonstrates efficacy as an HMG-CoA reductase inhibitor. This innovation holds promise for effectively treating conditions linked to hypercholesterolemia.

Career Highlights: Frederick C. Novello's career is marked by his tenure at Merck & Company, Inc., where he tirelessly dedicated his efforts to advancing medicinal chemistry. His contributions have led to significant improvements in cholesterol management treatments, showcasing his commitment to enhancing public health through innovation.

Collaborations: Throughout his career, Novello has collaborated with esteemed colleagues, including John J. Baldwin and Edward J. Cragoe, Jr. These partnerships have played a pivotal role in the evolution and success of his inventions, fostering an environment of collaborative innovation at Merck & Company, Inc.

Conclusion: Frederick C. Novello's impressive track record of 27 patents reflects his dedication to innovation in the field of pharmaceutical inventions. His latest developments in cholesterol synthesis inhibitors exhibit his ingenuity and the potential impact of his work on healthcare. His collaborations and contributions continue to inspire future innovations in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…